Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
10.98
+0.28 (2.62%)
Feb 21, 2025, 4:00 PM EST - Market closed
Forte Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Forte Biosciences stock have an average target of 77.58, with a low estimate of 64 and a high estimate of 100. The average target predicts an increase of 606.56% from the current stock price of 10.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 4, 2024.
Analyst Ratings
The average analyst rating for Forte Biosciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $64 | Strong Buy | Maintains | $64 | +482.88% | Dec 4, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3 → $64 | Strong Buy | Maintains | $3 → $64 | +482.88% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +583.06% | Aug 19, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +810.75% | May 30, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-16.45
from -24.92
EPS Next Year
-7.57
from -16.45
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -7.07 | -3.61 | -2.28 | |||
| Avg | -16.45 | -7.57 | -2.82 | |||
| Low | -21.32 | -14.95 | -3.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.